PubMed Health⌕ Search

PubMed · 16633550

Dihydrogen Activation by Titanium Sulfide Complexes.

Abstract

The titanocene sulfido complex Cp*(2)Ti(S)py (1, Cp* = pentamethylcyclopentadienyl; py = pyridine) is synthesized by addition of a suspension of S(8) to a toluene solution of Cp*(2)Ti-(CH(2)CH(2)) (2) and py. The rate of rotation of the pyridine ligand in solution was determined by (1)H NMR spectroscopy, and the structure of 1 was determined by X-ray crystallography. Complex 1 reacts reversibly with dihydrogen to give Cp*(2)Ti(H)SH (6) and py. Reaction of 1 with HD gives an equilibrium mixture of Cp*(2)Ti(D)SH and Cp*(2)Ti(H)SD; H(2) and D(2) are not formed in this reaction. 1D (1)H NMR magnetization transfer spectra and 2D EXSY (1)H NMR spectra of 6 in the presence of H(2) show that in solution the H(2), hydride, and hydrosulfido hydrogen atoms exchange. A four-center mechanism for this exchange is proposed. The EXSY studies show that the Ti-H and S-H hydrogens exchange with each other more rapidly than either of those hydrogens exchanges with external H(2). A transient dihydrogen complex intermediate is proposed to explain this observation. The infrared spectrum of 6 shows an absorption assigned to the Ti-H stretching mode at 1591 cm(-1) that shifts upon deuteration to 1154 cm(-1). Reaction of 1 with trimethylsilane, diethylsilane, or dimethylsilane gives Cp*(2)-Ti(H)SSiMe(3) (7), Cp*(2)Ti(H)SSiHEt(2) (8), or Cp*(2)Ti(H)SSiHMe(2) (9), respectively. The isotope effect for the reaction producing 7 has been measured, and a mechanism is proposed. Treatment of 1 with an additional equivalent of S(8) results in the formation of the disulfide Cp*(2)Ti(S(2)) (4). Acetylene inserts into the Ti-S bond of 4 to produce the vinyl disulfide complex 5. The structures of 4 and 5 have been determined by X-ray diffraction. Compound 4 reacts with 2 in the presence of py to produce 1. Phosphines react with 4 in the presence of H(2) to provide 6 and the corresponding phosphine sulfide. Reaction of hydrogen with 4 gives Cp*(2)-Ti(SH)(2) (3). The reactions of 1 and 4 with dihydrogen provide a model for possible mechanisms of H(2) activation by metal-sulfide hydrodesulfurization catalysts.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zachary K Sweeney, Jennifer L Polse, Robert G Bergman, Richard A Andersen. 1999-12-20. Dihydrogen Activation by Titanium Sulfide Complexes.. https://doi.org/10.1021/om9907876

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗